REGENSBURG, Germany--(BUSINESS WIRE)--Artilysin®, a new and innovative technological approach in the fight against pathogenic and multi-resistant bacteria, developed by the research & development company Lysando, has arrived in the pharmaceutical industry. Boehringer Ingelheim Vetmedica has secured the licensing rights for the technology platform Artilysin®. The company is hopeful to receive significant momentum and solutions from this new substance class for the problem of multi-resistant bacteria, which also is an increasing threat to the animal world.
Artilysin®s are proteins that, through a physical mechanism, selectively eliminate pathogenic, multi-resistant and persisting bacteria. By way of license, Boehringer Ingelheim Vetmedica is taking advantage of the possibilities presented by this technology. The scope of applications for Artilysin®s spans from human and animal medicine to the food industry and the area of hygiene. They work quickly and with their “friend or foe” identification very specifically and are completely biodegradable. Additionally, no resistances occurred during the expansive studies. Multi-resistant bacteria pose a significant threat to health due to the increasing ineffectiveness of antibiotics. The EU Commission estimates the annual number of deaths caused by multi-resistant bacteria at 25,000. Massive economic effects are linked to this fact.
The Boehringer Ingelheim Group is among the 20 leading pharmaceutical companies worldwide. Their focus areas include research & development, production and marketing of new medicines with significant therapeutic benefits for human and animal health. In 2013, Boehringer Ingelheim reported revenues of appr. 14.1 bn Euros.
Lysando itself is not a manufacturer of pharmaceutical products nor will it become one in the future; it only provides its new technology platform through licensing. „The acquisition of licensing rights for the Artilysin® technology by Boehringer Ingelheim Vetmedica is a decisive step in the acceptance of this new class of substances“, explains Markus Matuschka v. Greiffenclau, CEO of Lysando AG.
Lysando AG is a technology leader in the area of antimicrobial proteins. Since its foundation in 2009, the privately financed research company has done research on artificial designer proteins with a team of scientists in the town of Regensburg. Artilysin®s represent a revolutionary breakthrough in the battle against multi-resistant bacteria. With this new technology platform, drugs and substances against pathogenic gram-negative and gram-positive bacteria can be specifically developed, both for antibiotic-resistant and persisting bacteria. With Artilysin®s, Lysando has created an effective alternative to antibiotics.